Alkermes plc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $480.1 million (+21.8% year over year) and diluted EPS of $0.09. It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
480
+21.8%
|
16
-80.3%
|
0.09
-81.6%
|
|
Jul 28, 2026
28 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
496
+27.0%
|
1
-99.4%
|
0.00
-100.0%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
393
+28.2%
|
-66
-395.9%
|
-0.40
-407.7%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
385
-10.6%
|
49
-66.3%
|
0.29
-67.0%
|
|
Oct 22, 2025
22 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
394
+4.2%
|
83
-10.4%
|
0.49
-10.9%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
391
-2.1%
|
87
-4.7%
|
0.52
-1.9%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
307
-12.5%
|
22
-39.0%
|
0.13
-38.1%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
430
+13.9%
|
147
+29.9%
|
0.88
+29.7%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALKS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Dublin 4, Ireland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1520262
- Former names
- ANTLER SCIENCE TWO PLC (until Aug 5, 2011); Antler Science Two Ltd (until Aug 2, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.